GTCR completes Cord Blood sale to AMAG Pharma

GTCR said Monday that it completed the sale of Cord Blood Registry to AMAG Pharmaceuticals Inc. for $700 million. San Bruno, California-based Cord Blood is the newborn stem cell company. The deal was announced in June. Houlihan Lokey served as CBR’s financial advisor while Deutsche Bank Securities Inc. and Jefferies LLC served as AMAG’s financial advisors.

DealsNorth AmericaUSBriefs